| Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ... New England Journal of Medicine 378 (6), 518-528, 2018 | 967 | 2018 |
| Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet L Malcovati, E Hellström-Lindberg, D Bowen, L Adès, J Cermak, ... Blood, The Journal of the American Society of Hematology 122 (17), 2943-2964, 2013 | 793 | 2013 |
| Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel T De Witte, D Bowen, M Robin, L Malcovati, D Niederwieser, ... Blood, The Journal of the American Society of Hematology 129 (13), 1753-1762, 2017 | 362 | 2017 |
| Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide MA Dimopoulos, A Anagnostopoulos, MC Kyrtsonis, K Zervas, C Tsatalas, ... Journal of Clinical Oncology 25 (22), 3344-3349, 2007 | 345 | 2007 |
| Renal failure in multiple myeloma: incidence, correlations, and prognostic significance V Eleutherakis-Papaiakovou, A Bamias, D Gika, A Simeonidis, A Pouli, ... Leukemia & lymphoma 48 (2), 337-341, 2007 | 313 | 2007 |
| Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, ... The Lancet Oncology 18 (2), 241-250, 2017 | 260* | 2017 |
| Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 … MA Dimopoulos, E Terpos, M Boccadoro, S Delimpasi, M Beksac, ... The Lancet Oncology 22 (6), 801-812, 2021 | 248 | 2021 |
| Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the … E Kastritis, K Zervas, A Symeonidis, E Terpos, S Delimbassi, ... Leukemia 23 (6), 1152-1157, 2009 | 240 | 2009 |
| Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents MA Dimopoulos, S Delimpasi, E Katodritou, A Vassou, MC Kyrtsonis, ... Annals of oncology 25 (1), 195-200, 2014 | 175 | 2014 |
| High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents E Terpos, E Katodritou, M Roussou, A Pouli, E Michalis, S Delimpasi, ... European journal of haematology 85 (2), 114-119, 2010 | 160 | 2010 |
| Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del (5q): a multicenter study U Germing, M Lauseker, B Hildebrandt, A Symeonidis, J Cermak, ... Leukemia 26 (6), 1286-1292, 2012 | 149 | 2012 |
| Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients E Terpos, A Mougiou, A Kouraklis, A Chatzivassili, E Michalis, ... British journal of haematology 118 (1), 174-180, 2002 | 142 | 2002 |
| A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS P Fenaux, V Santini, MAA Spiriti, A Giagounidis, R Schlag, A Radinoff, ... Leukemia 32 (12), 2648-2658, 2018 | 136 | 2018 |
| Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study E Kastritis, M Gavriatopoulou, MC Kyrtsonis, M Roussou, E Hadjiharissi, ... Blood, The Journal of the American Society of Hematology 126 (11), 1392-1394, 2015 | 129 | 2015 |
| Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation N Kröger, R Brand, A Van Biezen, A Zander, J Dierlamm, D Niederwieser, ... haematologica 94 (4), 542, 2009 | 129* | 2009 |
| Recurrent ETNK1 mutations in atypical chronic myeloid leukemia CB Gambacorti-Passerini, C Donadoni, A Parmiani, A Pirola, S Redaelli, ... Blood, The Journal of the American Society of Hematology 125 (3), 499-503, 2015 | 125 | 2015 |
| Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression A Tichelli, G Socié, J Marsh, R Barge, N Frickhofen, S McCann, ... Annals of internal medicine 137 (3), 164-172, 2002 | 123* | 2002 |
| A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes U Platzbecker, A Symeonidis, EN Oliva, JS Goede, M Delforge, J Mayer, ... Leukemia 31 (9), 1944-1950, 2017 | 122 | 2017 |
| Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease M Biegstraaten, TM Cox, N Belmatoug, MG Berger, T Collin-Histed, ... Blood Cells, Molecules, and Diseases 68, 203-208, 2018 | 120 | 2018 |
| Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the … A Symeonidis, A Van Biezen, L de Wreede, A Piciocchi, J Finke, D Beelen, ... British journal of haematology 171 (2), 239-246, 2015 | 105 | 2015 |
Meletios Athanasios DimopoulosNational and Kapodistrian University of Athens, School of MedicineVerified email at med.uoa.gr
